Search results
Aug 9, 2010 · Studies in multiple countries have shown that the use of potentially inappropriate medications, such as those on the PRISCUS list, elevates the risk of adverse events. The avoidance of such medications would presumably improve the safety of pharmacotherapy for the elderly.
- Stefanie Holt, Sven Schmiedl, Petra A. Thürmann
- 10.3238/arztebl.2010.0543
- 2010
- 2010/08
Jan 9, 2023 · The new version is called PRISCUS 2.0 and lists substances that are potentially inappropriate medications (PIM) for the elderly (1). Multimedication, especially in patients of advanced age, has recently been a prominent topic in research publications and in medical training courses on applied pharmacotherapy.
For cases in which the administration of a PIM is clinically necessary, the final PRISCUS list contains recommendations for clinical practice, e.g. monitoring of laboratory values and dose adaptation. Therapeutic alternatives are also listed.
- Stefanie Holt, Sven Schmiedl, Petra A. Thürmann
- 2010
Jan 9, 2023 · The term potentially inadequate medication (PIM) is used to describe substances that may be unsuitable for use in the elderly and should be avoided. The PRISCUS list, published in 2010, was the first catalog of PIM designed for the German drug market to become adopted in practice.
- 10.3238/arztebl.m2022.0377
- 2023/01
- Dtsch Arztebl Int. 2023 Jan; 120(1-2): 3-10.
The following pages of this issue of Deutsches Ärzteblatt International contain the long-awaited update of the well-known PRISCUS list, presented by the team led by Petra Thürmann of Witten ...
Jan 9, 2023 · The PRISCUS list, published in 2010, was the first catalog of PIM designed for the Germandrug market to become adopted in practice. While 24% of German patients aged ≥ 65 years were prescribed at least one PIMper year in 2009, the proportion in 2019 was only 14.5%.
People also ask
What is a Priscus list?
What is the new Priscus version?
Should a drug be on the Priscus list?
What is the final Priscus list?
Review of the prevalence of identified possible inappropriateness of PIMs in German older patients using claims data selected drugs for older. lack of evidence is often criticised in PIM lists patients.